IL-25 (IL-17E
) is a recently identifi ed member of the IL-17 family of cytokines (1) . It has been implicated in the initiation of type 2 immunity by driving the expression of IL-4, IL-5, and IL-13 (1, 2) . In vitro, IL-25 is found in activated Th2 cells, bone marrow-derived mast cells, and alveolar macrophages (1, 3, 4) . Recently, we identifi ed that IL-25 is produced by a population of CD4 + cells in mouse caecal patches (5) . Expression of this cytokine is critical for immunity against helminth infections (5, 6) . IL-25 protein administration or transgenic overexpression of IL-25 in mice resulted in Th2-like responses associated multiorgan infl ammation characterized by elevated ex pression of IL-4, IL-5, and IL-13, infl ammatory cell infi ltration, and epithelial cell hyper plasia (1, 2, 7, 8) .
These fi ndings suggest that IL-25 may be an important mediator of type 2 immune pathologies.
Besides IL-25, there are fi ve additional members that belong to the IL-17 family of cytokines. Although IL-25 promotes allergic responses, IL-17A had been characterized to promote chronic infl ammatory responses (9, 10) . We have recently reported that IL-17A is produced by a population of IL-23-dependent pathogenic T cells required for the induction of autoimmune infl ammation (11) (12) (13) . This fi nding has led to the proposal that these IL-17-producing cells (called Th17) represent a novel subset of CD4 + Th cells (14) (15) (16) (17) . Several recent reports have demonstrated that TGF-β and IL-6 are required for lineage commitment of IL-17-producing T cells (18) (19) (20) , and this novel diff erentiation pathway does not share transcription regulatory elements with Th1 and Th2 responses (21, 22) . Indeed, we have identifi ed an orphan nuclear receptor-retinoidrelated orphan receptor γt (RORγt)-as the cri tical transcription regulator that controls TGF-β-and IL-6-induced Th17 diff erentiation (23) . These remarkable fi ndings provide defi nitive evidence that Th17 cells are indeed a bona fi de T cell subset that is independently regulated from Th1 and Th2.
Experimental autoimmune encephalomyelitis (EAE) is an autoimmune infl ammatory disease of the central nervous system (CNS) that serves as a disease model for human multiple sclerosis. EAE can be induced by passive transfer of myelin antigen-specifi c Th17 or Th1, but not Th2 cells (13, 24, 25) . In the infl amed CNS, high levels of proinfl ammatory cytokines, such as IL-17, IL-18, IFNγ, TNF, and IP10 are expressed with very low levels of Th2 cytokines such as IL-4 and -13 (26, 27) . Studies have documented that redirecting the Th cell balance toward a type 2 response can suppress autoimmunity (28) (29) (30) . It is well accepted that type 2 responses provide multiple signals that inhibit IFNγ-producing Th1 cells (31, 32) . Recent in vitro studies have suggested that Th17 cells are also negatively regulated by IL-4 signaling pathways (21, 22) . Nevertheless, very little is known about the in vivo regulation of Th17 cells. By generating IL-25-defi cient mice, we investigated whether this potent Th2-promoting cytokine plays a physiological role in regulating the development and function of Th1 and/or Th17 encephalitogenic T cells.
RESULTS

IL-25 is locally expressed in the CNS and protects from EAE
IL-25 is a potent cytokine that drives the production of type 2 cytokines such as IL-4, IL-5, and IL-13 (1). During EAE priming, a broad range of cytokines is induced in C57BL/6 mice, including the proinfl ammatory cytokines IFNγ, IL-17, and IL-18, as well as the type 2 cytokines IL-4 and IL-13. To determine whether IL-25 plays a regulatory role during autoimmune infl ammation, we analyzed the expression of this cytokine during the course of EAE. We observed that IL-25 mRNA is expressed in normal spinal cord as well as infl amed CNS (Fig. 1 A) . Analysis of CNS-resident cells indicated that IL-25 is predominantly expressed by microglia in the normal CNS (Fig. 1 B) . Remarkably, microglia expressed ninefold more IL-25 mRNA during active EAE. In contrast, infl ammatory macrophages or infi ltrating T cells do not express detectible levels of IL-25 (unpublished data).
We generated IL-25-defi cient mice (Fig. S1 , available at http://www.jem.org/cgi/content/full/jem.20061738/DC1) to determine whether this cytokine has a role in regulating clinical EAE. These mice have no developmental defects, and they generate litters of normal size. Males and females are born in equivalent numbers. Analysis of IL-25-defi cient spleens showed normal numbers and percentages of B cells, T cells, and granulocytes. IL-25-defi cient thymi had the same number of cells and the same percentages of CD4 and CD8 double-negative, single-positive, and double-positive thymocytes, when compared with C57BL/6 mice.
After myelin oligodendrocyte glycoprotein (MOG) peptide/ CFA immunization, IL-25-defi cient (il25 −/− ) mice showed accelerated EAE onset and enhanced disease severity compared with WT C57BL/6 mice ( Fig. 1 C) . il25 −/− mice consistently developed EAE 2-3 d earlier than WT mice, and all died (100% mortality at day 17) when immunized at doses optimized to give WT mice a nonlethal disease. In addition, incidence of disease reached 100% 6 d earlier in the il25 −/− group (Fig. 1 C) . Administration of IL-25 to MOG-immunized il25 −/− completely protected the mice from EAE (Fig. S1 C) , confi rming that no other defects are responsible for the enhanced susceptibility of il25 −/− mice to EAE. These results indicate that IL-25 may play an important role in suppressing the infl ammatory responses that drive EAE pathogenesis.
IL-25 inhibits the Th17 response within the CNS
We have recently described an IL-23-dependent, IL-17-producing T cell population that is highly pathogenic in autoimmune infl ammatory diseases (13) . Here, we found the 
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same Th17 cells as well as IFNγ-producing T cells in the CNS of il25 −/− mice at an earlier time point and in greater numbers than in the WT mice (Fig. 2) . 2 d before expected disease onset, the CNS of il25 −/− mice contained fi vefold more IL-17 + cells compared with the WT (Fig. 2 A) . In contrast, the total numbers of IFNγ-producing T cells were similar in the il25 −/− and WT control mice. Also, the total number of infl ammatory macrophages was comparable between il25 −/− and WT mice (Fig. S2 , available at http://www.jem .org/cgi/content/full/jem.20061738/DC1). At the peak of disease, the il25 −/− mice continue to have greater numbers of IL-17-producing T cells as well as IFNγ and TNF producers (Fig. 2 B) .
To examine whether the disease exacerbation observed in the il25 −/− mice was mediated by Th17 and/or Th1 cells, we injected anti-IL-17 or anti-IFNγ antagonist mAbs into EAEprimed mice. Blockade of IL-17 dramatically inhibited EAE, indicating that Th17 cells play a major role in EAE pathogenesis in il25 −/− mice (Fig. 2 C) . In contrast, anti-IFNγ treatment had no eff ect, consistent with studies demonstrating that Th1 cells only play a minor role in EAE (13) . Thus, the absence of IL-25 leads to a more rapid and intense infi ltration of pathogenic Th17 cells into the target organ, which drives an accelerated and exacerbated disease phenotype.
IL-25 is crucial for Th2 cytokine expression in the periphery
During EAE priming, myelin antigen-specifi c T cells are generated in lymph nodes draining the sites of immunization. In these lymphoid organs, T cell diff erentiation is dependent on the cytokines produced by antigen-presenting cells.
In draining lymph node (DLN) cells from il25 −/− mice, we found a twofold higher expression of IL-23p19 mRNA than in WT controls at day 7 after immunization ( Fig. 3 A) . Interestingly, the expression of IL-12p35 was not regulated by IL-25. To determine whether IL-25 aff ected T cell priming and T cell subset diff erentiation, we cultured DLN cells at day 7 after immunization in the presence of MOG peptide to assess myelin antigen-specifi c T cell responses. The Th2 cytokines IL-4, -5, and -13 were signifi cantly reduced in DLN cultures from il25 −/− mice. IL-17 and IFNγ levels were slightly higher in il25 −/− DLN cultures; however, the difference did not reach statistical signifi cance (Fig. 3 B) . In addition to Th2 responses, regulatory T cells play a crucial role in limiting chronic infl ammation. We found that il25 −/− mice generated Foxp3 + regulatory T cells in numbers similar to WT controls during the course of EAE (Fig. 3 C) . These data suggest that IL-25 plays a role in driving IL-4, IL-5, and IL-13 production but does not aff ect regulatory T cell development.
Exogenous IL-25 inhibits EAE development and progression
We next determined whether exogenous IL-25 can suppress acute as well as relapse-remitting EAE. We used replicationdefi cient adenoviral vectors (rAdVs) to induce local CNS or systemic IL-25 expression (33) . SJL mice were used for these studies because they exhibit a multiple relapse-remitting pattern of clinical disease. Using rAdV gene transfer vectors, we found that intracerebral delivery of IL-25-rAdV 1 d before immunization fully protected SJL mice from EAE (Fig. 4 A) . Mice treated with GFP-control-rAdV were not protected. An intracerebral injection of 3 × 10 9 viral particles ( Table S1 , available at http://www.jem .org/cgi/content/full/jem.20061738/DC1). We next examined whether IL-25 treatment can inhibit the eff ector phase of CNS infl ammation using a passive transfer model of EAE. Recombinant adenoviral vector-mediated IL-25 expression prevented EAE development when the treatment was given at the time of cell transfer, or even 3 d after cell transfer (Fig. 4 C) .
In multiple sclerosis, patients usually suff er from episodes of clinical disease relapse separated by periods of remission. Because IL-25-rAdV could protect from EAE when administered at either the priming stage (day 1 treatment) or during the eff ector stage (day 10 treatment), we tested whether IL-25 could be used therapeutically to modify clinical disease. Remarkably, we found that IL-25-rAdV completely blocked EAE relapse when the treatment was given after the fi rst episode of paralysis (Fig. 4 D) . In contrast, control-rAdV-treated mice suff ered two rounds of disease relapse over a period of 51 d. Collectively, these results suggest that besides its ability to prevent disease, IL-25 may regulate eff ector T cells and reduce their pathogenic functions.
IL-25 induced Th2 and suppressed Th17 responses
IL-25-defi cient mice exhibited increased Th17 responses that promoted severe EAE pathology (Fig. 2) . This result led us to examine the in vivo mechanisms of action of IL-25 treatment during disease induction. Daily s.c. injection with mouse IL (mIL)-25 protected the cytokine-treated mice from EAE ( Fig. 5 A) as compared with saline-treated C57BL/6 mice as well as il25 −/− mice. Given that the severe disease observed in il25 −/− mice appeared to be driven by IL-17 rather than IFNγ (Fig. 2 C) , we examined whether IL-25 could inhibit EAE in ifng −/− mice. Indeed, IL-25 treatment protected ifng −/− mice from EAE, suggesting that IL-25 regulation of the Th17 pathway is independent of IFNγ (Fig. 5 B) .
To further characterize the immune responses regulated by IL-25, we profi led the ex vivo gene expression pattern of DLN cells 7 d after MOG/CFA priming. We observed a marked down-regulation of IL-17 in IL-25-treated C57BL/6 
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as well as ifng −/− mice (Fig. 5 C) . Both genotypes showed an increased expression of IL-13 after IL-25 treatment. Interestingly, IL-25 did not regulate the expression of total IFNγ mRNA levels in response to priming with MOG peptide and CFA. It is notable that most of the IFNγ response in the DLNs is directed against the mycobacterial component of the adjuvant (only 1-2% MOG-specifi c T cell response and up to 10-30% anti-mycobacterial response). Thus, it is important to determine the myelin-specifi c T cell response. The in vitro MOG-specifi c cytokine recall analysis showed that DLN cells from IL-25-treated mice produced less IL-17 and IFNγ as compared with saline-treated controls (Fig. 5 D) . Type 2 cytokines such as IL-4, IL-5, and IL-13 were markedly increased in IL-25-treated animals. Intracellular cytokine staining of DLN cell cultures revealed lower relative and absolute numbers of IL-17-producing CD4 + T cells in IL-25-treated ifng −/− as well as C57BL/6 mice ( Fig. 5 E) . These fi ndings established that treatment with recombinant IL-25 can suppress autoimmune infl ammation by inducing Th2 while suppressing Th1 and Th17 responses.
IL-13 is required for IL-25-mediated protection from EAE and Th17 suppression
Previous studies as well as data shown here have demonstrated that IL-25 strongly induced expression of IL-4 and -13, which are potent EAE inhibitors (27, 34) . Therefore, we determined whether IL-25 suppression of EAE required the presence of these type 2 cytokines. Daily injection of mIL-25 protein protected Il4 −/− mice from EAE (Fig. 6 A) . However, IL-25 could not provide protection to Il13 −/− mice (Fig. 6 B) . The requirement for IL-13 signaling was confi rmed by using il4ra −/− mice, which cannot respond to either IL-4 or IL-13. As shown in Fig. 6 C, IL-25 protein failed to protect the il4ra −/− mice as well. These fi ndings show that IL-13 plays an important role in IL-25-mediated suppression of EAE.
Following the observation that IL-25 regulates EAE through suppression of Th17 responses, we used an in vitro cell culture system to further investigate the underlying mechanism. Naive DO11.10 CD4 + T cells were cocultured with LPS-activated CD11c + DCs in the presence of neutralizing antibodies against IFNγ and IL-4. Addition of IL-23 to these cultures induced 10% of IL-17-producing T cells (Fig.  6 D) , whereas untreated cultures only contained 0.3% of IL-17 producers (not depicted). The frequency of Th17 cells induced by IL-23 was reduced by half when the cells were grown in the presence of IL-25, showing that IL-25 blocked the in vitro Th17 response, independent of IL-4 (Fig. 6 D) . We also observed that IL-25 dramatically enhanced IL-13 production, even in the presence of IL-23, anti-IL-4, and anti-IFNγ (Fig. 6 E) .
We next determined the role of IL-13 in regulating Th17 cells. We observed a reduction of the IL-23-induced IL-17 production after addition of IL-25 (Fig. 6 F) . This inhibitory eff ect of IL-25 on IL-17 production was completely abolished by the addition of neutralizing antibodies against IL-13 ( Fig. 6 F) . Moreover, blockade of IL-13 led to enhanced IL-17 production. Addition of recombinant IL-13 to IL-23-driven cultures reduced IL-17 production similar to the eff ects of adding recombinant IL-25 (Fig. 6 F) . We confi rmed that IL-13 is a suppressor of IL-17 production using cells from MOG TCR transgenic mice (Fig. 6 G) . Because the IL-13 receptor is not expressed on T cells (35), we examined the eff ects of IL-13 on DC function. Remarkably, IL-13 suppressed LPS-mediated IL-23, IL-1, and IL-6 expression, which are required for Th17 diff erentiation and function (Fig. 6 H) . Collectively, these data demonstrate that IL-25 mediates EAE protection as well as Th17 suppression via IL-13. In turn, IL-13 directly suppresses DC production of Th17-promoting factors.
D I S C U S S I O N
In organ-specifi c autoimmunity, the balance of cytokines is a key determinant of resistance or susceptibility. In EAE, disease susceptibility is thought to correlate with the expression of proinfl ammatory cytokines such as IL-17, IFNγ, TNF, IL-6, and IL-1β. On the other hand, Th2 cytokines such as IL-4 and IL-13 have been shown to be important for preventing or ameliorating disease (26, 27, 36 ). In the current study, we show that IL-25, a Th2-promoting cytokine, can protect mice from EAE, and loss of IL-25 results in enhanced proinfl ammatory cytokine production and accelerated CNS pathology. This accelerated disease is also associated with an increased number of IL-17-, IFNγ-and TNF-producing T cells that invade the CNS. Even though IFNγ-producing cells can induce EAE and their presence within the CNS likely contributed to acute infl ammation, neutralization of IFNγ in il25 −/− mice did not lead to disease amelioration. In contrast, anti-IL-17 mAb treatment signifi cantly inhibited EAE in il25 −/− mice, suggesting that the IL-17 immune pathway plays an important role in the disease process. We also demonstrate that IL-25 treatment protects mice from EAE, and this protection clearly depends on the suppression of IL-17-producing T cells. Thus, the presence of IL-25 supports a cytokine environment that limits chronic infl ammatory responses.
IL-25 is constitutively expressed in the CNS (37). Interestingly, EAE-resistant BALB/c mice constitutively expressed higher CNS levels of IL-25 mRNA compared with moderately susceptible C57BL/6 (unpublished data). In addition, we found that resident microglia is a primary cellular source of IL-25 in a normal CNS. Importantly, there is a ninefold induction of IL-25 expression in microglia during CNS infl ammation. This IL-25 expression pattern supports the hypothesis that microglia have protective roles during chronic CNS infl ammation. The observation of tissue-specifi c expression of IL-25 is consistent with our recent study in a helminth infection model, where we showed that locally expressed IL-25 is crucial for the ability of mice to clear the gut parasite Trichuris muris (5). Moreover, IL-25 is also constitutively expressed in the lungs (1). Again, highly specialized tissue-resident cells, in this case, alveolar macrophages, were shown to be the source of IL-25 (4). Thus, IL-25 is expressed in organ systems where regulation of infl ammation is of critical importance. In healthy digestive and respiratory tracts, an anti-infl ammatory environment has to be maintained because of the constant exposure to commensal microbes. In immune-privileged sites, such as the eyes or the CNS, infl ammation must be constrained because of the detrimental consequences of tissue swelling responses in these organs. 
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During EAE priming, IL-25 induces IL-4, IL-5, and IL-13 in the periphery. Although IL-4 and IL-13 have been reported to be protective in EAE, there is little evidence that IL-5 plays a regulatory role in EAE (38) . In contrast, the role of IL-4 in suppressing organ-specifi c autoimmunity is well documented (29, 33, (39) (40) (41) . IL-4 is required for the diff erentiation of Th cells toward the Th2 pathway (42, 43) . In EAE, deviation of the immune system toward a Th2 response correlates with disease resistance (44, 45) , and delivery of IL-4 in vivo can modulate the immune response to ameliorate disease (29, 46) . Surprisingly, IL-25 treatment still protected il4 −/− mice from EAE, suggesting that the levels of IL-4 induced by IL-25 treatment are not suffi cient for EAE suppression. In contrast to IL-4, we found that IL-13 is necessary for IL-25-mediated EAE suppression. Both IL-4Rα-(required for IL-13 signaling) and IL-13-defi cient mice were not protected by IL-25 treatment, suggesting that IL-25 is acting via IL-13 to suppress disease. On its own, IL-13 protects rats from EAE, through its ability to deactivate infl ammatory macrophages, as well as suppressing the production of nitric oxide, IL-1β, and TNF (27) .
Here, we demonstrate a novel role for IL-13 in inhibiting Th17 diff erentiation and function. However, IL-13 can only partially inhibit IL-17 production. In contrast, IL-4 can completely block IL-17 response, consistent with two recent reports (21, 22) . These results suggest that IL-13 and IL-4 may use diff erent mechanisms to inhibit Th17 cells. Indeed, although T cells are shown to express the shared IL-4/IL-13 receptor chain IL-4Rα, the specifi c IL-13 receptor is not expressed on T cells (35) . Therefore, IL-13 might act by inhibiting DC function (27) . Indeed, we observed that IL-13 blocked Th17-promoting factors such as IL-1β, IL-6, and IL-23.
It is intriguing that in our Th17 cultures (DC-derived IL-6, IL-1β, TGF-β plus exogenous IL-23, anti-IL-4, and anti-IFNγ), IL-25 still induced IL-13 production. We have observed that IL-25 led to IL-13 production in CD4 + T cell populations in vitro (unpublished data). However, it is still unclear which T cell populations are responsive to IL-25 in vivo. It is also possible that IL-25 acts on NKT cells, which play an important role in the early IL-4 production during an immune response (47, 48) . NKT cells secrete IL-4, IL-13, and IFNγ upon activation and have an important immunoregulatory role (49, 50) . Interestingly, activation of NKT cells by the synthetic ligand α-galactosylceramide can induce IL-4 and IL-13, which protects mice from autoimmune infl ammation (51) (52) (53) . Another possible target of IL-25 may be antigen-presenting cells such as DCs. The IL-25 receptor, IL-17RB, has been found to be up-regulated in DCs under Th2-inducing conditions (54) . Consistent with pervious reports (55, 56), we observed that IL-25 could induce IL-13 mRNA expression in cultured DCs (unpublished data). Further studies are needed to understand how these IL-13-expressing cells regulate Th17 development.
We have shown that although IL-25 and IL-17 are members of the same cytokine family, they play opposing roles in the regulation of organ-specifi c autoimmunity. The type 2 responses promoted by IL-25 drive a novel regulatory mechanism for controlling Th17 responses. Unexpectedly, this regulation relies on IL-13 rather than IL-4, suggesting that IL-13 may be secreted at higher levels in the target organs during autoimmune infl ammation. This protective mechanism is important because the lack of IL-25 causes devastating infl ammatory responses during EAE. Thus, IL-25 expression by CNS-resident microglia may provide an important mechanism that limits brain and spinal cord infl ammation. This unique property suggests that IL-25 may be a potential therapeutic agent for a range of organ-specifi c infl ammatory disorders.
MATERIALS AND METHODS
Animals. il25 −/− mice were generated in the C57BL/6 background (Fig.  S1) . A C57BL/6J genomic BAC library (Genome Systems) was screened with a full-length mIL-25 cDNA probe, and a positive clone was identifi ed and used to generate a shotgun plasmid library (SeqWright). Subclones were sequenced and assembled to generate 15,747 bp of sequence encompassing the il25 locus. Using a genomic subclone (F6), a BglII site was introduced in exon1 at the ATG via site-directed mutagenesis. This clone was digested with BglII, and a 5,442-bp 5′ region of homology was cloned into the unique BglII site of pbgal-basic (CLONTECH Laboratories, Inc.). A 1,049-bp 3′ region of homology was generated by PCR using a genomic subclone (C6) incorporating unique SpeI and NotI restriction sites and cloned into pBSlox-Neo-lox. This plasmid was digested with SalI, and the lox-Neo-lox-3′ region of homology was ligated into the unique SalI site of the 5′ armpbgal-Basic, yielding the fi nal targeting vector. The NheI-linearized targeting vector was electroporated into C57BL/6 ES cells, and Neo-resistant clones were analyzed for homologous recombination (HR) using a PCR-based screening strategy followed by Southern blot confi rmation with 5′ and 3′ probes. A confi rmed HR clone was electroporated with a Cre recombinase expression-containing plasmid, and several Neo-sensitive clones were screened using Southern blot to identify the Neo-fl ipped HR il25-LacZ ES line. This line was injected into C57BL/6 blastocysts, and il25-LacZ-KI −/− progeny were obtained by intercrossing il25-LacZ-KI +/− animals. A PCR-based genotyping strategy was developed to track the il25 WT and knockin alleles.
il25-targeted allele, sense, 5′-G C T G A C T C T C A A C A T T C T A C T C C T C C -3′, and antisense, 5′-C C T G C T G C T T C A G G T A G G G C T T T G -3′; WT il25 allele, sense, 5′-C T A C A G A C A G G C T C C C A C A T G G A C C -3′, and antisense, 5′-C C T G C T G C T T C A G G T A G G G C T T T G -3′.
C57BL/6J and il4 −/− (C57BL/6-Il4 tm1Nnt /J) mice were obtained from The Jackson Laboratory. il13 −/− , ifng −/− , and DO11.10 × Rag −/− mice were from the DNAX colonies. Breeding pairs of il4ra −/− mice were obtained from F. Brombacher (University of Cape Town, Rondebosch, South Africa) and a colony maintained at DNAX. C57BL/6 MOG 33-55 TCR transgenic mice were obtained from T. Backstrom (Malaghan Institute of Medical Research, Wellington, New Zealand). Animals were maintained in a specifi c pathogen-free environment and tested negative for pathogens in routine screening. All experiments were performed following the guidelines of the DNAX Institutional Animal Care and Use Committee.
EAE induction.
For studies in gene-defi cient mice, we used the C57BL/ 6-MOG 33-55 model of EAE, as il25 −/− , ifng −/− , il4 −/− , il4ra −/− , and il13 −/− were bred on a C57BL/6 background. C57BL/6 mice were immunized with 100 μg MOG For administration into the CNS, rAdV gene transfer vectors were suspended in 10 μl PBS and injected into the right-lateral cerebral ventricle using a 28-gauge needle, as described previously (33) . For peripheral delivery, rAdVs suspended in 100 μl PBS were injected into the tail vein. Antibodies for neutralization of IFNγ (clone XMG1.2, rIgG1; 200 μg per mouse) and IL-17 (clone 1D10, rIgG1; 1 mg per mouse) and the corresponding isotype control (rat IgG1; 1 mg per mouse) were administered s.c. once a week starting 1 d before immunization.
Isolation of CNS infl ammatory cells. C57BL/6 mice were immunized as described. At day 7 (before disease onset) and at peak disease (day 11 in the il25 −/− and day 14 in WT), mice were killed, and CNS-infi ltrating T cells, macrophages, and resident microglia were isolated by digesting brain and spinal cord homogenate with collagenase and DNase followed by Percoll gradient centrifugation as described previously (57) . We determined the number of CD4 + CD45 hi T cells and CD4 − CD11b + CD45 hi infl ammatory macrophages in the CNS by multiplying the percentage of lineage markerpositive cells by the total number of mononuclear cells isolated from the CNS. For further characterization, intracellular cytokine staining was performed (see the following section). For analysis of IL-25 mRNA expression in the CNS, infl ammatory macrophages and resident microglia were isolated from irradiation bone marrow chimeric mice produced by the injection of CD45.1 B6 bone marrow cells into irradiated CD45.2 C57BL/6 mice. The CD11b + CD45.1 hi CD45.2 neg infl ammatory macrophages and CD11b + CD45.2 lo CD45.1 neg resident microglia (radiation-resistant cells remaining with the host CD45 allotype) were purifi ed by three-color fl ow cyto metric sorting from >100 irradiation bone marrow chimeric mice (11) . Purifi ed and sorted cells from naive or diseased animals were pooled (microglia or infl ammatory macrophages) and analyzed by quantitative realtime PCR for IL-25.
Intracellular staining. CNS-infi ltrating cells were obtained from MOG/ CFA-immunized mice as described in the previous paragraph. Cells were stained with anti-CD4-FITC, fi xed, and permeabilized with Cytofi x/Cytoperm (BD Biosciences). Intracellular staining with antibodies against IL-17, IFNγ, and TNF (BD Biosciences) was performed and analyzed by fl ow cytometry. T cells were identifi ed by gating on CD4. The number of cytokineproducing cells was calculated from the percentage of cytokine-positive CD4 + T cells. We determined the number of CD4 + T cells in the CNS by multiplying the percentage of lineage marker-positive cells by the total number of mononuclear cells isolated from the CNS. For intracellular cytokine staining of DLN cells, DLNs were taken at day 7 after immunization. After 3 d of culture with MOG, cells were incubated with IL-2 for 2 d. Cells were then incubated with PMA/ionomycin in the presence of Golgi-Plug (BD Biosciences) for 5 h, and intracellular staining was performed as described. Absolute cell numbers were obtained by multiplying relative numbers with total number in culture plate well. For intracellular Foxp3-staining, DLNs were taken at day 7 after immunization and processed immediately for CD4, CD25, and Foxp3 staining with the Mouse regulatory T cell staining kit (eBioscience).
Cytokine assays. Mice were immunized as described. DLNs (axillary, brachial, and inguinal) were isolated at day 7, before disease onset. Single-cell suspensions were plated at 6 × 10 6 cells/well in 24-well plates in the presence of 100 μg/ml MOG 33-55 peptide in cRPMI. Supernatants were collected after 3 d of culture. Cells were rested for 4 d in the presence of 1-2 ng/ml IL-2. After 7 d, cells were restimulated with 10 μg/ml αCD3 (plate bound) plus 5 μg/ml αCD28, and supernatants were collected at 24 and 72 h. Alternatively, supernatants were collected at 48 h after restimulation. Cytokine production was analyzed by sandwich ELISA (IL-13 and IL-17 kits; R&D Systems) or cytometric bead array (Mouse Th1/Th2 cytokine CBA and Infl ammation CBA kits; BD Biosciences). For the CBA assay, 50 μl of supernatant was incubated with a mixture of beads coated with capture antibodies for IL-2, IL-4, IL-5, IFNγ, or TNF (for Th1/Th2 kit), or IL-6, IL-10, MCP-1, IFNγ, TNF, or IL-12p70 (for Infl ammation kit). Addition of the PE-conjugated detection antibodies forms a sandwich complex. After 2 h of incubation and one wash, samples were analyzed by fl ow cytometry. Standard curves were generated from analysis of titrated cytokine standards (at least 10 serial dilutions) using the BD CBA analysis software, which runs on Excel (Microsoft). IL-13 and IL-17 in samples from in vitro Th17 assays were assessed using a multiplexing bead array (Linco) according to the manufacturer's recommendations. In brief, 25 μl of supernatants were incubated with assay buff er, and fl uorescent beads were conjugated to capture antibodies for the cytokines of interest. After addition of the detection antibody mix and PE-conjugated streptavidin, plates were read on a LUMINEX 100 machine (Luminex). Data were analyzed using Masterplex QT (MiraiBio) and GraphPad Prism (GraphPad).
Histological analysis. Spinal cords were taken at day 18 after immunization. Fixated tissue was embedded in paraffi n wax, and 5-μm-thick longitudinal sections were stained with hematoxylin and eosin. Lesions were counted, and each scored based was on the size of the infl ammatory infi ltrate (score 1, <10 cells; score 3, 10-50 cells; score 5, >50 cells). The total number of lesions was assessed per section, and mean and SD were calculated per treatment group. Cumulative score per section was divided by total number of lesions to obtain a mean lesion score per section. Mean and SD were calculated per treatment group.
Quantitative real-time PCR. DLN were taken at day 7 after immunization from fi ve mice per indicated group and processed in three diff erent pools. Singlecell suspensions were prepared by mashing lymph nodes through a 70-μm cell strainer (BD Biosciences). CNS leukocytes were prepared and purifi ed as described. DC cultures were prepared as stated in the following section. Total RNA was prepared from frozen cell pellets using RNeasy columns (QIAGEN), and 5 μg were subjected to treatment with DNase (Ambion) and reverse transcribed using Superscript II (Invitrogen) with oligo (dT)15 primers (Roche) and random hexamers (Promega). Cytokine-specifi c mRNA was measured by realtime quantitative PCR (Applied Biosystems). Gene expression levels were normalized to ubiquitin.
In vitro cultures. Spleens and lymph nodes were taken from naive DO11.10 × RAG −/− BALB/c mice, which only produce OVA peptidespecifi c naive T cells. Cells were also isolated from naive C57BL/6 MOG 33-55 TCR Tg (clone 2D2) mice or from WT C57BL/6 mice (for DC isolations). CD4 + as well as CD11c + cells were purifi ed by magnetic bead separation (MACS; Miltenyi Biotec) after collagenase digestion of tissue. For Th17 polarization, CD11c + cells (5 × 10 5 cells per well in a 24-well plate) were activated with 0.5 ng/ml LPS and incubated with OVA peptide as well as neutralizing antibodies against IL-4 (BVD4-1D11; 10 μg/ml) and IFNγ (XMG1.2; 10 μg/ml) for 2 h before addition of CD4 + cells in a 1:1 ratio. 20 ng/ml IL-23 was added to expand Th17 cells. Depending on the experimental setup, 100 ng/ml IL-25, 100 ng/ml IL-3, or 10 μg/ml anti-IL-13 were added to the cultures. Cultures with no cytokine addition served as a control. After 72 h, cells were incubated with 5 ng/ml IL-2 for an additional 48 h. Supernatants were then sampled for cytokine analysis, and cells were stimulated with PMA/ionomycin for 5 h in the presence of Golgi-Plug (BD Biosciences). Intracellular staining for IL-17 was performed as described. For DC cultures, 10 6 CD11c + DCs were plated in a 48-well plate, rested overnight, and incubated with or without IL-13 1 h before addition of LPS. Cells were harvested after 24 h and prepared for gene expression analysis.
Online supplemental material. Fig. S1 contains a schematic representation of the WT il25 locus, the arms used for generating the targeted allele, and the ARTICLE Neo-fl ipped-LacZ knockin allele. Fig. S2 shows similar numbers of CNSinfi ltrating infl ammatory macrophages and total T cells in WT versus il25 −/− mice at several time points after MOG-EAE induction. Table S1 summarizes the results of the analysis of spinal cord sections from IL-25-treated versus untreated EAE mice (experiment shown in Fig. 4 B) 
